TET2 and myeloproliferative neoplasm: In addition to ARCH/CHIP, DNMT3A, TET2, and ASXL1 mutations are frequently detected in several myeloid malignancies, including MDS, MDS/MPN, and AML [73–75], suggesting that these mutations are the earliest events during malignant transformation.